Citations

Clear

2 citation(s) found for "Singh, Gagan".

Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Lurz, Philipp , Hahn, Rebecca T. , Kodali, Susheel , Makkar, Raj , Sharma, Rahul , Davidson, Charles J. , O’Neill, Brian , Yadav, Pradeep , Zahr, Firas , Chadderdon, Scott , Eleid, Mackram F. , Smith, Robert L, Garcia, Santiago , Kister, Tobias , Kipperman, Robert, Lim, Scott, Hermiller, James, Mishell, Jacob M. , Rassi, Andrew N., Szeto, Wilson Y. , Babaliaros, Vasilis , Barker, Colin M. , Summers, Matthew , Chetcuti, Stanley, Ailawadi, Gorav , Russo, Mark, Rinaldi, Michael, Chehab, Bassem , Nickenig, Georg, Stinis, Curtiss, Inglessis‐Azuaje, Ignacio , Dhoble, Abhijeet , Petrossian, George , Shah, Pinak, Staniloae, Cezar , Nores, Marcos, Singh, Gagan D. , Baldus, Stephan , Rudolph, Volker , Barb, Ilie, Klodell, C.T., Gray, William A. , Strote, Justin A, Sannino, Anna , Grayburn, Paul , Mack, Michael J. , Leon, Martin B. , Thourani, Vinod H. , Lim, D. Scott , Szerlip, Molly , Kister, Tobias , Lim, D Scott , Saxon, John , Kapadia, Samir , Mishell, Jacob M , Herrmann, Howard C , Hausleiter, Jörg , Babaliaros, Vasilis , Barker, Colin M , Lindman, Brian R , Latib, Azeem , von Bardeleben, Ralph Stephan , Summers, Matthew , Ailawadi, Gorav , Rinaldi, Michael , Chehab, Bassem M , Nickenig, Georg , Inglessis-Azuaje, Ignacio , Dhoble, Abhijeet , Chhatriwalla, Adnan K , Petrossian, George , Shah, Pinak , Staniloae, Cezar , Williams, Mathew , McCabe, James M , Singh, Gagan , Baldus, Stephan , Rudolph, Volker , Klodell, Charles , Gray, William , Strote, Justin , Sannino, Anna , Grayburn, Paul , Mack, Michael J , Thourani, Vinod H , Davidson, Charles J. , Hahn, Rebecca T , Lurz, Philipp , Smith, Robert L, Whisenant, Brian K. , Kapadia, Samir , Hausleiter, Jörg , Lindman, Brian R. , Latib, Azeem , Muhammad, Kamran I. , Williams, Mathew

Mayo Clinic

European Heart Journal | August 21, 2025 | Volume: 47 | Issue: 17 | Pages: 2059-2073

10.1093/eurheartj/ehaf676 | PMID 40878717 Get It

Abstract Background and Aims The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.
The Impact of Setons on Perianal Fistula Outcomes in Patients With Crohn's Disease Treated With Anti‐TNF Therapy: A Multicentre Study
Munir, Javeria, Parlow, Simon , Sambhi, Gagan Deep Singh, Reid, Jacqueline, Yanofsky, Russell , Alenezi, Talal , Meserve, Joseph , Yeh, Kuan‐Hung, Becker, Brenda, Lahijanian, Zubin, Eddin, Anas Hussam, Mallick, Ranjeeta , Rosenfeld, Greg , Bessissow, Ali, Bruining, David H. , Macdonald, Blair , Singh, Siddharth, Parlow, Simon , Jairath, V , McCurdy, Jeffrey D , Yeh, Kuan‐Hung, Ramsay, Tim , Bessissow, Talat , Jairath, Vipul , Macdonald, Blair

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 18, 2025 | Volume: 61 | Issue: 10 | Pages: 1671-1679

10.1111/apt.70081 | PMID 40098436 Get It

ABSTRACTBackground and AimsWe aimed to assess the impact of setons on perianal fistula outcomes in patients with perianal fistulising Crohn's disease (PFCD) treated with anti‐TNF therapy.MethodsWe included patients treated with their first anti‐TNF therapy for PFCD after undergoing a pelvic MRI between 2005 and 2022 from 6 North American centres. Our exposure was one or more setons at the time of anti‐TNF therapy. Our primary outcome was major adverse fistula outcome (MAFO), a composite of repeat local surgical intervention, hospitalisation, or faecal diversion for PFCD, and our secondary outcome was fistula remission defined clinically. We used 1:1 cardinality matching and propensity score weighting to control for fistula severity based on centrally read MRIs, luminal characteristics, and concomitant therapies.ResultsOur analysis included 221 patients: 81 with setons and 140 without setons. After cardinality matching, our cohorts were balanced (standardised difference < 0.1 for all covariates). Patients with setons had similar rates of MAFO (HR 1.23; 95% CI, 0.68–2.21) and fistula remission at 6 months (OR, 0.81; 95% CI, 0.41–1.59) and 12 months (OR, 0.63; 95% CI, 0.31–1.27) compared to patients without setons. Our results remained stable when analysed by propensity score weighting and in a sensitivity analysis of patients who underwent an exam under anaesthesia. In patients with abscesses, there were lower rates of MAFO (HR, 0.49; 95% CI, 0.19–1.25) but not statistically significant in patients with setons.ConclusionsIn this multicentre, setons were not associated with improved fistula outcomes. Future prospective controlled studies are warranted.